Published in Neoplasia on May 01, 2010
Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration. Neoplasia (2012) 0.89
Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression. Mutat Res (2012) 0.80
Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma. Cancer Sci (2015) 0.79
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications. Genes (Basel) (2016) 0.79
Identification of a Selective G1-Phase Benzimidazolone Inhibitor by a Senescence-Targeted Virtual Screen Using Artificial Neural Networks. Neoplasia (2015) 0.79
Decreased expression of transcription elongation factor A-like 7 is associated with gastric adenocarcinoma prognosis. PLoS One (2013) 0.78
Mathematical model of a telomerase transcriptional regulatory network developed by cell-based screening: analysis of inhibitor effects and telomerase expression mechanisms. PLoS Comput Biol (2014) 0.78
The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype. Genes (Basel) (2016) 0.75
Dinosaurs and ancient civilizations: reflections on the treatment of cancer. Neoplasia (2010) 0.75
The interconnectedness of cancer cell signaling. Neoplasia (2011) 0.75
Evaluation Analysis of miRNAs Overexpression in Liquid-Based Cytology Endometrial Samples. J Cancer (2017) 0.75
Reflecting on 25 years with MYC. Nat Rev Cancer (2008) 7.44
Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell (1993) 5.28
An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol (2003) 4.49
Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell (1993) 4.10
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell (2007) 3.23
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol (2008) 2.30
Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet (2003) 2.26
A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res (2005) 1.95
C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene (2008) 1.70
c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene (2007) 1.59
Facilitating replication under stress: an oncogenic function of MYC? Nat Rev Cancer (2009) 1.56
Telomerase activation by c-Myc in human mammary epithelial cells requires additional genomic changes. Cell Cycle (2009) 1.52
Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res (2006) 1.44
Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res (2003) 1.36
Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer (2004) 1.24
Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene (2005) 1.24
Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res (2005) 1.23
A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene (2009) 1.14
Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res (2008) 1.02
Chromatin remodeling: recruitment of histone demethylase RBP2 by Mad1 for transcriptional repression of a Myc target gene, telomerase reverse transcriptase. FASEB J (2009) 1.00
High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer (2008) 0.98
Integrated nanosensors to determine levels and functional activity of human telomerase. Neoplasia (2008) 0.98
A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation. Oncogene (2008) 0.97
Butein suppresses c-Myc-dependent transcription and Akt-dependent phosphorylation of hTERT in human leukemia cells. Cancer Lett (2009) 0.89
The MYCN oncoprotein as a drug development target. Cancer Lett (2003) 0.89
Dynamic telomerase gene suppression via network effects of GSK3 inhibition. PLoS One (2009) 0.88
The role of recombination in telomere length maintenance. Biochem Soc Trans (2009) 0.85
Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer. Gynecol Oncol (2009) 0.84
Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy. Neoplasia (2005) 0.82
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52
Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res (2007) 3.19
miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res (2009) 2.52
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol (2012) 2.36
Rational design of shepherdin, a novel anticancer agent. Cancer Cell (2005) 1.74
A role for NANOG in G1 to S transition in human embryonic stem cells through direct binding of CDK6 and CDC25A. J Cell Biol (2009) 1.67
Breast cancer stem cells: an overview. Eur J Cancer (2006) 1.61
miR-21: an oncomir on strike in prostate cancer. Mol Cancer (2010) 1.54
Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy (2011) 1.54
Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis (2007) 1.50
Targeting survivin in cancer therapy. Expert Opin Ther Targets (2008) 1.47
Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res (2006) 1.44
Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms. Biochim Biophys Acta (2009) 1.36
Gastrokine 1 is abundantly and specifically expressed in superficial gastric epithelium, down-regulated in gastric carcinoma, and shows high evolutionary conservation. J Pathol (2004) 1.34
Towards the definition of prostate cancer-related microRNAs: where are we now? Trends Mol Med (2009) 1.24
Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res (2005) 1.23
Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest (2002) 1.12
Dimerizable redox-sensitive triazine-based cationic lipids for in vitro gene delivery. ChemMedChem (2007) 1.12
The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU Int (2012) 1.11
Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica (2009) 1.10
p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res (2002) 1.07
MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin Ther Targets (2011) 1.07
Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol (2010) 1.07
Characterization of novel antisense HIF-1α transcripts in human cancers. Cell Cycle (2011) 1.06
A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria. BMC Blood Disord (2004) 1.05
Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J Med Chem (2006) 1.03
Involvement of NF-Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene. FEBS Lett (2003) 1.02
Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res (2008) 1.02
G-quadruplex structures in the human genome as novel therapeutic targets. Molecules (2013) 1.02
TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects. Cancer Res (2011) 1.00
Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol (2003) 1.00
XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). J Hematol Oncol (2014) 0.99
Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene (2004) 0.99
Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur J Cancer (2005) 0.98
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther (2005) 0.97
Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer (2010) 0.96
Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies. Int J Cancer (2008) 0.96
Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res (2005) 0.96
The PTEN regulator DJ-1 is associated with hTERT expression in clear cell renal cell carcinoma. Int J Cancer (2009) 0.96
Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther (2006) 0.96
Synthesis and antitumor activity of 3-(2-phenyl-1,3-thiazol-4-yl)-1H-indoles and 3-(2-phenyl-1,3-thiazol-4-yl)-1H-7-azaindoles. ChemMedChem (2011) 0.93
miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts. Antioxid Redox Signal (2013) 0.92
Hybrid ligand-alkylating agents targeting telomeric G-quadruplex structures. Org Biomol Chem (2012) 0.92
Redox-active polymer microcapsules for the delivery of a survivin-specific siRNA in prostate cancer cells. ACS Nano (2011) 0.92
A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Res (2003) 0.91
Emerging role of microRNAs in prostate cancer: implications for personalized medicine. Discov Med (2010) 0.91
Photochemical internalization: a new tool for drug delivery. Curr Pharm Biotechnol (2007) 0.91
Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res (2012) 0.90
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochem Pharmacol (2012) 0.90
Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cell. Regen Med (2006) 0.90
Telomeres as targets for anticancer therapies. Expert Opin Ther Targets (2011) 0.89
Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies. Nat Clin Pract Oncol (2004) 0.89
Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition. Biochem Pharmacol (2011) 0.89
Novel 1H-pyrrolo[2,3-b]pyridine derivative nortopsentin analogues: synthesis and antitumor activity in peritoneal mesothelioma experimental models. J Med Chem (2013) 0.89
Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer (2003) 0.89
Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr Med Chem (2013) 0.88
Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway. Curr Pharm Des (2013) 0.88
Dynamic telomerase gene suppression via network effects of GSK3 inhibition. PLoS One (2009) 0.88
MDM2 negatively regulates the human telomerase RNA gene promoter. BMC Cancer (2005) 0.87
Ectopically hTERT expressing adult human mesenchymal stem cells are less radiosensitive than their telomerase negative counterpart. Exp Cell Res (2007) 0.87
Induction of endoplasmic reticulum stress response by the indole-3-carbinol cyclic tetrameric derivative CTet in human breast cancer cell lines. PLoS One (2012) 0.87
Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem Pharmacol (2007) 0.87
Targeting the telosome: therapeutic implications. Biochim Biophys Acta (2009) 0.86
Autophagy acts as a safeguard mechanism against G-quadruplex ligand-mediated DNA damage. Autophagy (2012) 0.86
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer (2010) 0.86
Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αVβ3. J Med Chem (2012) 0.85
High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors. J Transl Med (2013) 0.85
Tethering functional ligands onto shell of ultrasound active polymeric microbubbles. Biomacromolecules (2006) 0.85
Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines. Int J Oncol (2007) 0.85
Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis (2004) 0.84
Characterization of stress response in human retinal epithelial cells. J Cell Mol Med (2012) 0.84
Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. PLoS One (2011) 0.83
Novel PVA-based hydrogel microparticles for doxorubicin delivery. Biomacromolecules (2008) 0.83
Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis (2003) 0.82
Telomerase-directed molecular therapeutics. Expert Rev Mol Med (2002) 0.82
Biomolecular markers of outcome prediction in prostate cancer. Cancer (2009) 0.82
Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells. Colloids Surf B Biointerfaces (2013) 0.82
Mechanisms of action and antiproliferative properties of Brassica oleracea juice in human breast cancer cell lines. J Nutr (2005) 0.82
The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines. Breast Cancer Res (2011) 0.81
To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys (2009) 0.81
Detection of telomerase hTERT gene expression and its splice variants by RT-PCR. Methods Mol Med (2004) 0.81
Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World J Gastrointest Oncol (2010) 0.81
Ribozyme-mediated inhibition of PKCalpha sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis. Prostate (2003) 0.81
A small molecule modulator of prion protein increases human mesenchymal stem cell lifespan, ex vivo expansion, and engraftment to bone marrow in NOD/SCID mice. Stem Cells (2012) 0.81
Photochemical internalization of a peptide nucleic acid targeting the catalytic subunit of human telomerase. Cancer Res (2003) 0.81
Mitochondria are primary targets in apoptosis induced by the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I) in melanoma cell lines. Biochem Pharmacol (2006) 0.81
YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation. Int J Cancer (2014) 0.80
Cytotoxic activity of 2-Fluoro-ara-AMP and 2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines. Int J Oncol (2010) 0.80
A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides. J Med Chem (2014) 0.80
Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. Int J Cancer (2013) 0.80
RNA interference-mediated validation of genes involved in telomere maintenance and evasion of apoptosis as cancer therapeutic targets. Methods Mol Biol (2009) 0.79
Breast cancer-initiating cells: insights into novel treatment strategies. Cancers (Basel) (2011) 0.79